Categories: Health Care

Torrent Pharma enters into licensing agreement with Medicine Patent Pool to manufacture and commercialise generic version of Pfizer Oral COVID-19 Treatment

New Delhi, March 20, 2022: Torrent Pharmaceuticals Limited (herein after referred to as “TPL”) has announced that it has signed a non-exclusive, non-transferable, non-sub licensable, license agreement to use the patents and know-how in relation to the compound nirmatrelvir with Medicine Patent Pool (herein after referred to as “MPP”) for manufacture and commercialisation of the generic version of PAXLOVID™ [product containing the compound nirmatrelvir (PF-07321332) to be co-packaged and co-administered with ritonavir] in 95 low and middle income countries including India for treatment and/or prevention of COVID-19 caused by SARS- CoV-2.

Earlier, MPP had entered into license agreement with PF Prism Holdings B.V. (Pfizer) granting MPP with the rights to sub-license manufacture and commercialisation rights to sub-licensees.

The oral COVID-19 treatment comprises of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations.

TPL will launch the product after obtaining necessary approval from Regulatory Agencies.

Pfizer markets its oral COVID-19 treatment under the name PAXLOVID™, which is authorized by U.S. Food and Drug Administration (FDA) [for Emergency Use Authorisation (EUA)] and the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of COVID-19 in patients at high-risk of progressing to serious illness.

Commenting on the arrangement, Aman Mehta (Executive Director) said: “We are pleased to enter into this agreement with MPP and is part of our continued endeavor to make Covid treatments as accessible as possible to patients.”

Corporate Comm India (CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

10 hours ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

1 day ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

4 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

5 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

6 days ago